BIAF ▲ +53.1% - bioAffinity Technologies, Inc. $BIAF bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors bioAffinity Technologies gained 53.1% today following news that the company is advancing its CyPath® Lung product for surveillance applications in lung cancer survivors. The expansion of CyPath® Lung into the post-treatment monitoring space represents a new clinical use case that could broaden the addressable market for the diagnostic technology. 01-SEP-2026 08:00 AM ET